INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,709,944 | +117.0% | 793,321 | +29.4% | 0.00% | +100.0% |
| Q2 2023 | $6,779,418 | -15.8% | 612,967 | +2.3% | 0.00% | 0.0% |
| Q1 2023 | $8,049,114 | +111137.1% | 599,338 | +2.5% | 0.00% | 0.0% |
| Q4 2022 | $7,236 | -99.9% | 584,994 | +30.6% | 0.00% | 0.0% |
| Q3 2022 | $6,246,000 | +3.5% | 447,778 | +2.4% | 0.00% | 0.0% |
| Q2 2022 | $6,037,000 | -5.6% | 437,207 | +11.2% | 0.00% | 0.0% |
| Q1 2022 | $6,395,000 | -18.7% | 393,063 | -18.6% | 0.00% | 0.0% |
| Q4 2021 | $7,863,000 | +6.4% | 482,740 | -3.0% | 0.00% | 0.0% |
| Q3 2021 | $7,389,000 | -24.3% | 497,636 | +1.8% | 0.00% | 0.0% |
| Q2 2021 | $9,758,000 | -8.6% | 488,665 | +5.6% | 0.00% | -50.0% |
| Q1 2021 | $10,675,000 | +6.7% | 462,540 | +14.2% | 0.00% | 0.0% |
| Q4 2020 | $10,006,000 | -40.0% | 405,127 | +0.8% | 0.00% | -33.3% |
| Q3 2020 | $16,667,000 | -12.3% | 402,015 | +1.4% | 0.00% | -25.0% |
| Q2 2020 | $18,994,000 | -21.1% | 396,462 | +3.7% | 0.00% | -33.3% |
| Q1 2020 | $24,080,000 | -73.0% | 382,469 | -46.8% | 0.01% | -33.3% |
| Q4 2019 | $89,044,000 | +303.7% | 718,564 | +116.2% | 0.01% | +80.0% |
| Q3 2019 | $22,058,000 | -15.7% | 332,414 | +1.1% | 0.01% | -16.7% |
| Q2 2019 | $26,152,000 | -15.8% | 328,670 | +18.4% | 0.01% | -25.0% |
| Q1 2019 | $31,058,000 | -40.7% | 277,658 | -46.6% | 0.01% | 0.0% |
| Q4 2018 | $52,386,000 | +74.3% | 519,772 | +118.6% | 0.01% | 0.0% |
| Q3 2018 | $30,051,000 | +63.3% | 237,827 | +8.4% | 0.01% | +33.3% |
| Q2 2018 | $18,406,000 | +81.0% | 219,360 | +32.7% | 0.01% | +100.0% |
| Q1 2018 | $10,170,000 | +9.0% | 165,316 | +3.5% | 0.00% | 0.0% |
| Q4 2017 | $9,327,000 | -0.6% | 159,666 | -1.2% | 0.00% | 0.0% |
| Q3 2017 | $9,379,000 | -49.0% | 161,605 | +6.4% | 0.00% | -57.1% |
| Q2 2017 | $18,395,000 | +12.8% | 151,941 | +5.4% | 0.01% | 0.0% |
| Q1 2017 | $16,301,000 | +17.5% | 144,130 | +12.8% | 0.01% | +16.7% |
| Q4 2016 | $13,878,000 | -30.0% | 127,738 | +6.0% | 0.01% | -40.0% |
| Q3 2016 | $19,831,000 | +17.9% | 120,490 | +2.2% | 0.01% | +11.1% |
| Q2 2016 | $16,818,000 | +16.1% | 117,877 | +4.5% | 0.01% | +12.5% |
| Q1 2016 | $14,487,000 | -11.1% | 112,773 | +3.3% | 0.01% | -11.1% |
| Q4 2015 | $16,296,000 | -4.5% | 109,119 | +6.1% | 0.01% | -10.0% |
| Q3 2015 | $17,062,000 | -15.3% | 102,874 | +23.2% | 0.01% | -16.7% |
| Q2 2015 | $20,154,000 | -4.5% | 83,499 | +11.6% | 0.01% | 0.0% |
| Q1 2015 | $21,104,000 | +110.0% | 74,833 | +16.2% | 0.01% | +100.0% |
| Q4 2014 | $10,050,000 | -31.9% | 64,427 | +3.3% | 0.01% | -40.0% |
| Q3 2014 | $14,757,000 | +1.4% | 62,350 | +1.4% | 0.01% | +11.1% |
| Q2 2014 | $14,557,000 | -25.1% | 61,518 | +4.3% | 0.01% | -30.8% |
| Q1 2014 | $19,448,000 | +383.9% | 58,973 | +0.2% | 0.01% | +333.3% |
| Q4 2013 | $4,019,000 | +47.8% | 58,861 | +49.4% | 0.00% | +50.0% |
| Q3 2013 | $2,719,000 | +151.3% | 39,389 | +63.2% | 0.00% | +100.0% |
| Q2 2013 | $1,082,000 | – | 24,130 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |